This site is intended for healthcare professionals

FDA approves Radicava ORS, oral suspension, to treat amyotrophic lateral sclerosis.- Mitsubishi Tanabe

Read time: 1 mins
Published:15th May 2022

Mitsubishi Tanabe Pharma Corporation announced that the FDA has approved Radicava ORS (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS) on May 12, 2022. Radicava ORS is an oral suspension formulation that contains the same active ingredient as edaravone for intravenous infusion (Japanese product name: Radicut Injection 30 mg and Radicut Bag for I.V. Infusion 30 mg) for ALS treatment and being developed globally, primarily by Mitsubishi Tanabe Pharma Development America, Inc.


The route of administration of edaravone is limited to intravenous infusion so far. With the approval of Radicava ORS, ALS patients have flexibility in how they take their medicine.

Condition: Amyotrophic Lateral Sclerosis/Lou Gehrig's Diseas
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.